Intracerebral hemorrhage (ICH) is the most lethal type of stroke, but there is no specific
treatment. After years of effort, neurologists have found that hematoma expansion (HE) is a …

Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor is an
established therapy for a broad spectrum of patients with cardiovascular disease. The …

Background Severe traumatic injury continues to present challenges to healthcare systems
around the world, and post-traumatic bleeding remains a leading cause of potentially …

Background Patients with spontaneous intracerebral hemorrhage (ICH) have a higher risk of
venous thromboembolism (VTE) and in-hospital VTE is independently associated with poor …

The use of antiplatelet therapy (APT) is prevalent among the general population, sometimes
without clear indications. We provided updated figures on the incidence and prognosis of …

Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral
hemorrhage (ICH) while the effect on functional outcome is uncertain. Methods and Results …

Background The avoidance of hematoma expansion is the most important therapeutic goal
during acute care of patients with intracerebral hemorrhage. Hematoma expansion occurs in …

Intracerebral hemorrhage (ICH) represents a major, global, unmet health need with few
treatments. A significant minority of ICH patients present taking an anticoagulant; both …

Objective: Current international guidelines offer a conditional recommendation to consider a
single dose of IV desmopressin (DDAVP) for antiplatelet-associated intracranial hemorrhage …

Spontaneous intracerebral hemorrhage (ICH) is a medical emergency with potentially
devastating morbidity and mortality. After ischemic stroke, ICH represents the second most …